Large Language Models in Biotech and Life Sciences

Q: Where does generative AI already ship in drug discovery, and where does it remain experimental?

Shipping applications: de novo molecule design (generative models — graph-based, transformer-based, diffusion-based — propose candidate molecules optimised for binding affinity, drug-like properties, synthetic accessibility; used by Pfizer, Roche, Novartis and dedicated biotechs Insilico Medicine, Atomwise, Exscientia for hit-generation and lead-optimisation phases); protein structure prediction AlphaFold class (AlphaFold-2, AlphaFold-3, ESMFold, RoseTTAFold predict protein structure from sequence at near-experimental accuracy; integrated into target-validation, drug-design, biologics pipelines); synthetic data for ML model training (generative models augment under-represented chemistries; improves downstream property-prediction); patent landscape analysis (LLMs for patent corpus, freedom-to-operate, prior-art search); scientific literature synthesis (LLMs for systematic-review acceleration, hypothesis generation, drug-repurposing candidate identification). Experimental: generative target identification (promising but not yet production); generative biologics design beyond folding (designs that match desired functional properties; advancing fast but production deployment uneven); generative formulation and process optimisation (promising in research; production rare); end-to-end autonomous discovery (closed-loop systems demonstrated in research; not standard); generative clinical-trial design (aspirational; regulatory engagement just beginning). Shipping vs experimental boundary in 2026 moving: what was experimental in 2023 — large-scale de novo molecule design integrated into pipelines — now production; what is experimental now likely production in 2027-2028 at leading sites.

Q: What is generative AI's role in medical imaging — synthesis, denoising, modality translation, diagnosis?

Roles by maturity. Synthesis production: generation of synthetic medical images to augment under-represented conditions; widely used in research and increasingly production for downstream classifier training; synthetic images not used directly for patient diagnosis. Denoising production: diffusion and other generative models for denoising low-dose CT, accelerated MRI, low-light ultrasound; reduces patient dose or imaging time; FDA-cleared products from GE HealthCare, Siemens Healthineers, Philips, Canon, Subtle Medical. Modality translation developing: MRI-to-CT, low-field to high-field MRI, ultrasound-to-MRI; reduces additional acquisitions; clinical deployment growing. Image segmentation production: generative-flavoured segmentation models for organ, lesion, structure segmentation. Super-resolution production: generative super-resolution for upsampling low-resolution acquisitions. Diagnostic generation experimental: direct generation of diagnostic reports or diagnoses from images; LLMs over imaging-derived features; production deployments rare and typically advisory-only. Image-to-image transformation for treatment planning developing: generative models for radiotherapy planning, surgical planning; clinical deployment growing. Validation requirement: all medical-imaging AI requires clinical validation against expert ground truth; many require regulatory clearance (FDA 510(k), CE marking). 2026 deployment pattern: synthesis and denoising production at scale; segmentation and super-resolution production in many applications; modality translation growing; diagnostic generation remains advisory and validation-gated. Vendor pattern: major imaging vendors integrate generative AI; specialised AI vendors (Subtle Medical, Aidoc, Annalise.ai, Lunit) provide complementary capabilities.

Q: How does AI in pharma quality control and manufacturing differ from AI in discovery?

Fundamental differences: regulatory framework (discovery AI operates pre-regulation — target identification, candidate selection happen before regulatory submission; manufacturing AI operates post-regulation — every change to manufacturing process subject to GMP, change control, regulatory notification); validation rigour (discovery validated against scientific success criteria — hit rate, lead-property targets; manufacturing validated against GAMP, CSV/CSA frameworks, with audit trails and inspection readiness); deployment timeline (discovery can deploy in weeks-to-months; manufacturing requires months of validation work); data type (discovery works on chemical, biological, biomedical data — sequences, structures, assay results, literature; manufacturing works on process data — sensor readings, vision images, deviation reports, batch records); model types (discovery uses chemistry-specific models — graph neural networks, transformer-based molecule models, protein-folding models; manufacturing uses computer-vision models for inspection, classical ML for predictive maintenance, NLP for deviation analysis); risk profile (discovery failure causes wasted research time; manufacturing failure can cause product-quality issues, patient harm, regulatory action); change-management (discovery models updated freely; manufacturing updates require change control, validation impact assessment, possibly regulatory notification); vendor ecosystem (discovery vendors often research-focused biotechs and academic spin-outs; manufacturing vendors often pharma-systems vendors — Werum, Tulip, Rockwell, Honeywell — with deep validation expertise). Shared challenges: data quality; talent; integration. Strategic distinction: discovery AI is differentiation (where breakthrough comes from); manufacturing AI is operational excellence (where cost reduction comes from); both have role; not substitutes.

Q: Which top AI applications in biotech are revenue-bearing in 2026, and which are still research?

Revenue-bearing 2026: AI-driven hit generation and lead optimisation (used across pharma; biotechs Insilico Medicine, Schrödinger, Atomwise, Exscientia, Recursion Pharmaceuticals, Relay Therapeutics have AI-discovered candidates in clinical trials; deal-flow with pharma mature); protein-folding-as-a-service (AlphaFold and successors integrated into commercial software and cloud services); AI-augmented medical imaging (imaging vendors charge for AI capabilities; specialised AI vendors monetise standalone analysis; reimbursement codes exist for some applications); pharma manufacturing AI (vision inspection, predictive maintenance, PAT — mature vendor market; multi-year contracts); AI-driven biomedical literature and patent analysis (Causaly, BenevolentAI, ChEMBL monetise literature-mining-as-a-service); AI for clinical-trial site selection and patient recruitment. Still-research 2026: closed-loop autonomous drug discovery (demonstrated; not productised at scale); AI for generative biologics design beyond AlphaFold class (advancing fast; vendor monetisation emerging but uneven); AI for end-to-end clinical-trial design (aspirational; regulatory engagement just beginning); personalised medicine and pharmacogenomics AI (research strong; commercial deployment uneven); AI-discovered novel therapeutic modalities — gene therapies, cell therapies designed by AI (early-stage; not mature commercial); real-world-evidence AI for post-market drug-effectiveness analysis (growing; commercial deployment uneven). 2026 revenue concentration: most revenue concentrated in small number of AI-native drug-discovery biotechs with mature pipelines and established vendors providing infrastructure (cloud GPU for ML, validated AI for manufacturing, imaging-AI platform vendors). Trajectory: research-to-revenue transitions happening; revenue-bearing list in 2027-2028 longer than 2026.

Introduction

Generative AI in life sciences is split between two narratives in 2026: the cure-cancer headlines and the operational reality. The headlines stall at the validation gate; the operational wins ship measurable improvements inside the regulatory envelope. This article walks the applied examples — de novo molecule design narrowing the discovery funnel, synthetic medical imaging augmenting under-represented conditions, large language models for biomedical knowledge work, AlphaFold-class tools embedded in classical pipelines, AI in pharma quality control. Each example names where it works, where it doesn’t, and what regulatory and validation work accompanies a production deployment (see the generative AI landing and life sciences landing for the broader programme).

What this means in practice

Discovery-funnel narrowing ships; cure-cancer headlines stall.
Medical-imaging synthesis is real; standalone diagnostic generation is not.
LLMs are powerful for knowledge work and structured extraction.
Regulatory and validation work is the deployment bottleneck.

Where does generative AI already ship in drug discovery, and where does it remain experimental?

The shipping applications in drug discovery:

De novo molecule design. Generative models (graph-based, transformer-based, diffusion-based) propose candidate molecules optimised for binding affinity, drug-like properties, synthetic accessibility. Used by major pharma (Pfizer, Roche, Novartis) and dedicated biotechs (Insilico Medicine, Atomwise, Exscientia) for hit-generation and lead-optimisation phases. Production-level integration; not exploratory.

Protein structure prediction (AlphaFold class). AlphaFold-2, AlphaFold-3, ESMFold, RoseTTAFold predict protein structure from sequence at near-experimental accuracy for many targets. Integrated into target-validation, drug-design, and biologics pipelines across the industry.

Synthetic data for ML model training. Generative models augment under-represented chemistries in ML training sets; improves downstream property-prediction model performance.

Patent landscape analysis. LLMs for patent corpus analysis, freedom-to-operate research, prior-art search.

Scientific literature synthesis. LLMs for systematic-review acceleration, hypothesis generation from literature, drug-repurposing candidate identification.

The experimental side:

Generative target identification. Generative approaches to novel target discovery; promising but not yet production for most teams.

Generative biologics design (antibodies, peptides, proteins beyond folding). Designs that match desired functional properties; advancing fast but production deployment uneven.

Generative formulation and process optimisation. Promising in research; production rare.

End-to-end autonomous discovery. Closed-loop systems combining generation, synthesis, testing, learning; demonstrated in research; not standard in major pharma.

Generative clinical-trial design. Trial-protocol generation and optimisation; aspirational, with regulatory engagement just beginning.

The shipping vs experimental boundary in 2026 is moving. What was experimental in 2023 (large-scale de novo molecule design integrated into pipelines) is now production. What is experimental now (closed-loop autonomous discovery) will likely be production in 2027-2028 at leading sites.

What is generative AI’s role in medical imaging — synthesis, denoising, modality translation, diagnosis?

The roles, by maturity:

Synthesis (production). Generation of synthetic medical images to augment under-represented conditions in training data; widely used in research and increasingly in production for downstream classifier training. Synthetic images are not used directly for patient diagnosis; they train the downstream classifier that does diagnosis.

Denoising (production). Diffusion and other generative models for denoising of low-dose CT, accelerated MRI, low-light ultrasound. Reduces patient dose or imaging time while preserving diagnostic quality. FDA-cleared products available from major imaging vendors (GE HealthCare, Siemens Healthineers, Philips, Canon, Subtle Medical, others).

Modality translation (developing). MRI-to-CT translation, low-field to high-field MRI translation, ultrasound-to-MRI translation; reduces need for additional acquisitions; clinical deployment growing.

Image segmentation (production). Generative-flavoured segmentation models (diffusion-based, transformer-based) for organ, lesion, structure segmentation; production across many imaging applications.

Super-resolution (production). Generative super-resolution for upsampling low-resolution acquisitions to high resolution; production in some applications.

Diagnostic generation (experimental). Direct generation of diagnostic reports or diagnoses from images; LLMs over imaging-derived features; production deployments rare and typically advisory-only.

Image-to-image transformation for treatment planning (developing). Generative models for radiotherapy planning, surgical planning; clinical deployment growing.

The validation requirement. All medical-imaging AI requires clinical validation against expert ground truth; many require regulatory clearance (FDA 510(k), CE marking, etc.) before clinical deployment. The validation requirement applies whether the model is discriminative or generative.

The 2026 deployment pattern. Synthesis and denoising are production at scale; segmentation and super-resolution production in many applications; modality translation growing; diagnostic generation remains advisory and validation-gated.

The vendor pattern. Major imaging vendors integrate generative AI capabilities into their platforms; specialised AI vendors (Subtle Medical, Aidoc, Annalise.ai, Lunit, others) provide complementary capabilities; the integration ecosystem is mature.

How does AI in pharma quality control and manufacturing differ from AI in discovery?

The fundamental differences:

Regulatory framework. Discovery AI operates pre-regulation (target identification, candidate selection happen before regulatory submission). Manufacturing AI operates post-regulation (every change to the manufacturing process is subject to GMP, change control, regulatory notification).

Validation rigour. Discovery AI is validated against scientific success criteria (hit rate, lead-property targets). Manufacturing AI is validated against GAMP, CSV/CSA frameworks, with audit trails and inspection readiness.

Deployment timeline. Discovery AI can deploy in weeks-to-months. Manufacturing AI requires months of validation work.

Data type. Discovery AI works on chemical, biological, biomedical data (sequences, structures, assay results, literature). Manufacturing AI works on process data (sensor readings, vision images, deviation reports, batch records).

Model types. Discovery AI uses chemistry-specific models (graph neural networks, transformer-based molecule models, protein-folding models). Manufacturing AI uses computer-vision models for inspection, classical ML for predictive maintenance, NLP for deviation analysis.

Risk profile. Discovery AI failure causes wasted research time. Manufacturing AI failure can cause product-quality issues, patient harm, or regulatory action.

Change-management. Discovery AI models can be updated freely (the next experiment uses the new model). Manufacturing AI model updates require change control, validation impact assessment, possibly regulatory notification.

Vendor ecosystem. Discovery AI vendors are often research-focused biotechs and academic spin-outs. Manufacturing AI vendors are often pharma-systems vendors (Werum, Tulip, Rockwell, Honeywell) with deep validation expertise.

The shared challenges:

Data quality. Both depend on data quality.

Talent. Both require AI talent that understands the life-sciences domain.

Integration. Both require integration with existing systems (electronic-lab-notebook for discovery; MES, LIMS, QMS for manufacturing).

The strategic distinction. Discovery AI is differentiation (where the breakthrough comes from). Manufacturing AI is operational excellence (where the cost reduction comes from). Both have a role; they are not substitutes.

Which top AI applications in biotech are revenue-bearing in 2026, and which are still research?

The revenue-bearing list (2026):

AI-driven hit generation and lead optimisation. Used across pharma; multiple biotechs (Insilico Medicine, Schrödinger, Atomwise, Exscientia, Recursion Pharmaceuticals, Relay Therapeutics, others) have AI-discovered candidates in clinical trials; deal-flow with pharma is mature.

Protein-folding-as-a-service. AlphaFold and successors integrated into commercial software and cloud services; pharma pays for predictions on novel sequences and complexes.

AI-augmented medical imaging. Imaging vendors charge for AI capabilities; specialised AI vendors monetise standalone analysis services; reimbursement codes exist for some applications.

Pharma manufacturing AI (vision inspection, predictive maintenance, PAT). Mature vendor market; multi-year contracts with pharma operations.

AI-driven biomedical literature and patent analysis. Multiple vendors (Causaly, BenevolentAI, ChEMBL, others) monetise literature-mining-as-a-service.

AI for clinical-trial site selection and patient recruitment. Vendors monetise patient-finding services; clinical-trial-operations platforms with AI capabilities.

The still-research list (2026):

Closed-loop autonomous drug discovery. Demonstrated; not productised at scale.

AI for generative biologics design beyond AlphaFold class. Advancing fast; vendor monetisation emerging but uneven.

AI for end-to-end clinical-trial design. Aspirational; regulatory engagement just beginning.

Personalised medicine and pharmacogenomics AI. Research strong; commercial deployment uneven.

AI-discovered novel therapeutic modalities (gene therapies, cell therapies designed by AI). Early-stage; not mature commercial.

Real-world-evidence AI for post-market drug-effectiveness analysis. Growing; commercial deployment uneven.

The 2026 revenue concentration. Most revenue from biotech AI is concentrated in (a) the small number of AI-native drug-discovery biotechs with mature pipelines and (b) the established vendors providing infrastructure (cloud GPU for ML, validated AI for manufacturing, imaging-AI platform vendors).

The trajectory. Research-to-revenue transitions are happening; the list of revenue-bearing applications in 2027-2028 will be longer than in 2026. The investment thesis behind much current biotech-AI funding is the bet on these transitions.

How do generative drug-design and protein-design tools (AlphaFold class) integrate with classical pipelines?

The integration patterns:

Target-validation integration. AlphaFold-predicted structures replace or augment crystallography-derived structures for target validation; classical docking, simulation, mutation analysis run against AlphaFold structures.

Hit-generation integration. Generative molecule models propose candidates; candidates filtered through classical chemistry filters (drug-like-property filters, synthetic-accessibility filters, ADMET predictors), classical docking against AlphaFold structures, classical assay design and execution.

Lead-optimisation integration. Generative models propose modifications to lead candidates; modifications filtered through classical evaluation (binding affinity prediction, ADMET prediction, synthesis-accessibility); experimentally validated in classical assays.

Biologics design integration. Generative protein models (AlphaFold-3, ProteinMPNN, RFdiffusion) propose protein variants; variants filtered through classical evaluation (folding stability, expression yield, off-target binding); experimentally validated.

Patent and prior-art integration. AI-generated candidates checked against patent landscape using classical patent-search tools augmented with LLM-based semantic search.

Lab-automation integration. AI-proposed candidates fed into lab-automation platforms for synthesis, assay execution, characterisation; results fed back to AI models for next iteration.

Decision-support integration. AI predictions presented to medicinal chemists, structural biologists, computational biologists as decision support; the human-in-the-loop decides what to synthesise and test.

The integration challenges:

Confidence calibration. AI-predicted properties have confidence intervals that classical assays do not; pipeline must reconcile.

Validation cost. AI predictions must be experimentally validated; the validation cost can exceed the AI savings if not managed.

False-positive rate. AI-generated candidate molecules may have high false-positive rates against classical filters; pipeline must filter aggressively before experimental validation.

Pipeline orchestration. AI predictions, classical filters, experimental execution must be orchestrated; mature pharma pipelines have ELN/LIMS integration; less-mature teams build custom orchestration.

Talent. Successful integration requires AI-fluent classical scientists and chemistry-fluent AI scientists; the cross-fluency is scarce.

The 2026 maturity. Major pharma and AI-native biotechs have mature integration; mid-tier pharma is investing; small biotechs without infrastructure struggle. The integration is the gating factor for many programmes, not the AI capability itself.

The vendor pattern. Pipeline-orchestration vendors (Schrödinger, OpenEye, BIOVIA, ChemAxon) integrate AI capabilities with classical chemistry pipelines. Cloud-native platforms (AWS Omics, Google Cloud Life Sciences) provide infrastructure for custom pipelines.

What clinical-trial and regulatory artefacts must accompany a GenAI medical-imaging deployment?

The required artefacts:

Intended-use statement. Specific clinical task, patient population, imaging modality, body part, intended outcome (diagnosis, screening, triage, decision support).

Risk classification. FDA risk class (Class I, II, III), EU MDR risk class, equivalent for other jurisdictions.

Predicate device or de novo pathway. For FDA 510(k), predicate device with established substantial equivalence; for novel applications, de novo pathway.

Pre-clinical validation. Performance against ground truth on representative dataset; sensitivity, specificity, AUC, calibration; reader study if comparing to human radiologist.

Clinical validation. Performance in clinical setting; may include reader study, prospective observational study, randomised controlled trial depending on risk class and claim type.

Algorithm description. Model architecture, training data characteristics, performance characteristics; sufficient detail for regulatory review without exposing trade secrets.

Software-as-medical-device (SaMD) documentation. IEC 62304 software lifecycle documentation, risk management per ISO 14971, quality management per ISO 13485.

Cybersecurity documentation. FDA cybersecurity guidance, EU MDR security requirements; vulnerability assessment, threat model, mitigation plan.

Adaptive AI considerations. For models that update post-deployment, predetermined change control plan (PCCP) describing acceptable changes without re-submission; FDA guidance specific to this.

Post-market surveillance plan. Performance monitoring in production, adverse event reporting, real-world performance reporting.

Labelling. Intended use, contraindications, performance characteristics, limitations, user training requirements; reviewed by regulator.

Quality management system. ISO 13485-compliant QMS covering design, development, manufacturing, post-market activities.

Clinical evaluation report. For EU MDR, comprehensive clinical evaluation summarising clinical evidence.

The jurisdictional differences:

FDA. 510(k), de novo, PMA pathways depending on risk class; PCCP for adaptive AI.

EU MDR. CE marking via notified body assessment; clinical evaluation report; post-market surveillance.

Other jurisdictions. PMDA (Japan), NMPA (China), Health Canada, MHRA (UK) — each with specific requirements.

The 2026 trend. Regulatory bodies have clarified AI-specific guidance significantly since 2022; the regulatory pathway is established for many imaging-AI applications; novel applications (generative diagnostic, autonomous decision-making) still require regulatory engagement.

The vendor pattern. Major imaging-AI vendors provide regulatory-ready packages; specialist AI startups partner with established medical-device companies for regulatory pathway. Going-it-alone for novel regulatory pathways is high-cost.

Limitations that remained

Validation is the bottleneck. The AI capability often outpaces the validation work; the deployment timeline is governed by validation, not by AI development.

Regulatory clarity is uneven. Established applications (vision inspection, denoising) have clear pathways; novel applications (autonomous decision-making, generative biologics for clinical use) have evolving pathways.

Data quality limits performance. AI quality is bounded by training data quality; for many applications, the data is the limit, not the algorithm.

Talent scarcity. AI-fluent life-sciences professionals and life-sciences-fluent AI professionals are both scarce; the cross-fluency is the bottleneck.

Cost of failed validation. AI projects that pass scientific validation but fail clinical or regulatory validation represent significant sunk cost; the failure rate is real.

How TechnoLynx Can Help

TechnoLynx works with biotech and pharma teams on generative-AI applications that fit within the validation and regulatory envelope. We focus on the operational wins — discovery-funnel narrowing, imaging augmentation, manufacturing AI — rather than the cure-cancer headlines. If your team is scoping a generative-AI life-sciences programme, contact us.

Image credits: Freepik